drugset / Trial / NCT03540901
Effect of Acetazolamide on Lung Water Content by Ultrasound in Patients With Respiratory Disease at Altitude
Phase 4
Completed
112 enrolled
University of Zurich
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This trial will evaluate the effect of acetazolamide (375 mg per day) vs. placebo on lung water content by ultrasound at acute altitude exposure in patients with Chronic Obstructive Pulmonary Disease (COPD).
Timeline
- Start
- 2018-05-22
- Primary completion
- 2018-08-02
- Completion
- 2018-08-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Acetazolamide | Small molecule | 375 mg | Oral |